China Sky One Medical, Inc. Has 11 New Drugs In Clinic Trials
China Sky One Medical, Inc. ("China Sky One Medical" or "the Company"), a leading fully integrated pharmaceutical company producing external use, over- the-counter drugs in the People's Republic of China ("PRC"), announced recently that it has 11 new drugs that have entered into clinical trials, including seven administered by injection.
China Sky One has a history of successfully producing external use drugs and has now set its sights on developing drugs for injection, a market where it sees a great deal of potential. Out of the 11 new drugs currently undergoing clinical trials that are listed below, seven of them are administered by injection:
- Povidone Iodine Suppository: for treatment of moniliasis colpitis, bacterial colpitis, and hemorrhoids;
- Gabexate Mesylate Injection: for treatment of acute pancreatitis and acute hemorrhagic necrosis of the pancreas;
- Ciclopirox Ointment: for treatment of superficial fungal infection, such as Tinea manuum and Tinea pedis;
- Ciclopirox Olamine Vaginal Suppositories: for treatment of moniliasis, or mycotic colitis.
- Fibrauretnire Suppositories: for treatment of vulvar moniliasis vaginosis;
- Omeprazole Sodium Injection: for treatment of digestive ulcers, gastrinoma, stress ulcers and Reflux Esophagitis. This drug can prevent stress states and upper postoperative digestive tract bleeding and aspiration pneumonitis by general anesthetics;
- Ozagrel Sodium Injection: for treatment of acute cerebral infarction and accompanied impediments;
- Citicoline Sodium Injection: for treatment of acute brain injury and postoperative consciousness impediment;
- Tiopronin Injection: for improving liver function from liver inflammation, fatty liver, alcoholic hepatitis, medication injury, and heavy metal detox. This drug can reduce toxic and side effects of chemotherapy and has a notable curative effect on cataracts and vitreous opacities in early stages
- Carbazochrome Sodium Sulfonate Injection: for treatment of the urinary system, upper digestive tract, respiratory system and obstetric hemorrhage;
- Diltiazem Hydrochloride Injection: for treatment of paroxysmal supraventricular tachycardia and unstable angina pectoris. This drug can also be used for high-blood pressure during an operation or for severe hypertension.
"We are very excited about our pipeline of newly developed drugs," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical, Inc. "They are now in clinical trials and we are confident that they can expand our market share and increase profitability going forward. Our move into the injectable drug delivery market represents a strong opportunity for future growth since the traditional injection is still a dominant delivery method. The testing for these drugs needs about six month to complete and may submit them to the SFDA for approval in the beginning of 2009."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit www.skyonemedical.com .
SOURCE: China Sky One Medical, Inc.